Poniard Pharmaceuticals, Inc.
PARD · OTC
12/31/2010 | 12/31/2009 | 12/31/2008 | 12/31/2007 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $2 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8 | $26 | $35 | $23 |
| G&A Expenses | $17 | $15 | $14 | $0 |
| SG&A Expenses | $17 | $15 | $13 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $0 |
| Other Operating Expenses | $3 | $3 | $0 | -$0 |
| Operating Expenses | $28 | $43 | $49 | $35 |
| Operating Income | -$28 | -$43 | -$49 | -$35 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $28 | $43 | $1 | $3 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30 | -$46 | -$49 | -$33 |
| % Margin | – | – | – | – |
| EPS | -26.4 | -52.4 | -56.4 | -43.2 |
| % Growth | 49.6% | 7.1% | -30.6% | – |
| EPS Diluted | -26.4 | -52.4 | -56.4 | -43.2 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $4 |
| Interest Expense | $2 | $3 | $2 | $2 |
| Depreciation & Amortization | $1 | $1 | $2 | $2 |
| EBITDA | -$25 | -$39 | -$48 | -$30 |
| % Margin | – | – | – | – |